24765-53-5 Usage
General Description
2-Methyl-2-phenylpropane-1,3-diol is a chemical compound with the molecular formula C10H14O2. It is also known as 2,2-dimethyl-2-phenylpropane-1,3-diol and is classified as a diol, which means it contains two hydroxyl (OH) functional groups. 2-methyl-2-phenylpropane-1,3-diol is used in a variety of industrial applications, including as a building block in the synthesis of other organic compounds. It is also used as a corrosion inhibitor and as a component in personal care and cosmetic products due to its hydrating properties. Additionally, 2-methyl-2-phenylpropane-1,3-diol is known to have antimicrobial properties, making it a useful ingredient in certain skincare and hygiene products.
Check Digit Verification of cas no
The CAS Registry Mumber 24765-53-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,4,7,6 and 5 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 24765-53:
(7*2)+(6*4)+(5*7)+(4*6)+(3*5)+(2*5)+(1*3)=125
125 % 10 = 5
So 24765-53-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H14O2/c1-10(7-11,8-12)9-5-3-2-4-6-9/h2-6,11-12H,7-8H2,1H3
24765-53-5Relevant articles and documents
Ashby,Noding
, p. 4792,4794,4796 (1979)
Isomerization of olefins triggered by rhodium-catalyzed C-H bond activation: Control of endocyclic β-hydrogen elimination
Yip, Stephanie Y. Y.,A?ssa, Christophe
, p. 6870 - 6873 (2015/06/02)
Five-membered metallacycles are typically reluctant to undergo endocyclic β-hydrogen elimination. The rhodium-catalyzed isomerization of 4-pentenals into 3-pentenals occurs through this elementary step and cleavage of two C-H bonds, as supported by deuterium-labeling studies. The reaction proceeds without decarbonylation, leads to trans olefins exclusively, and tolerates other olefins normally prone to isomerization. Endocyclic β-hydrogen elimination can also be controlled in an enantiodivergent reaction on a racemic mixture.
ARYLOXYALKYLAMINE NK-1/SSRI INHIBITORS
-
, (2010/02/15)
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.
